These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 3002661)

  • 21. Relationship between inhibition of cardiac muscle phosphodiesterases, changes in cyclic nucleotide levels, and contractile response for CI-914 and other novel cardiotonics.
    Weishaar RE; Quade MM; Schenden JA; Evans DB
    J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(6):551-64. PubMed ID: 3003170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of cyclic AMP-dependent protein kinase activity by the cardiotonic drugs amrinone and milrinone.
    Earl CQ; Linden J; Weglicki WB
    Life Sci; 1986 Nov; 39(20):1901-8. PubMed ID: 2430162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents.
    Weishaar RE; Burrows SD; Kobylarz DC; Quade MM; Evans DB
    Biochem Pharmacol; 1986 Mar; 35(5):787-800. PubMed ID: 3006691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle.
    Endoh M; Yamashita S; Taira N
    J Pharmacol Exp Ther; 1982 Jun; 221(3):775-83. PubMed ID: 6283063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of new inotropic agents on exercise performance.
    Weber KT; Janicki JS; Maskin CS
    Circulation; 1986 Mar; 73(3 Pt 2):III196-204. PubMed ID: 2867837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2.
    Colucci WS; Wright RF; Braunwald E
    N Engl J Med; 1986 Feb; 314(6):349-58. PubMed ID: 2418353
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacology of bipyridine phosphodiesterase III inhibitors.
    Honerjäger P; Nawrath H
    Eur J Anaesthesiol Suppl; 1992; 5():7-14. PubMed ID: 1600969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies on the mechanism of the cardiotonic activity of MDL 19205: effects on several biochemical systems.
    Kariya T; Wille LJ; Dage RC
    J Cardiovasc Pharmacol; 1984; 6(1):50-5. PubMed ID: 6199611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Some new positive inotropic agents.
    Andersson KE
    Acta Med Scand Suppl; 1986; 707():65-73. PubMed ID: 2874692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Species-dependent pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 58993 and WIN 62005.
    Dundore RL; Pagani ED; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
    J Cardiovasc Pharmacol; 1995 Jan; 25(1):14-21. PubMed ID: 7723343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of amrinone and enoximone on the subclasses of cyclic AMP phosphodiesterase from human heart and kidney.
    Masuoka H; Ito M; Nakano T; Naka M; Tanaka T
    J Cardiovasc Pharmacol; 1990 Feb; 15(2):302-7. PubMed ID: 1689427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular distribution and pharmacological sensitivity of low Km cyclic nucleotide phosphodiesterase isozymes in human cardiac muscle from normal and cardiomyopathic subjects.
    Silver PJ; Allen P; Etzler JH; Hamel LT; Bentley RG; Pagani ED
    Second Messengers Phosphoproteins; 1990; 13(1):13-25. PubMed ID: 2286932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacologic and pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 63291 and WIN 62582.
    Pagani ED; Dundore RL; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
    J Cardiovasc Pharmacol; 1994 Sep; 24(3):403-10. PubMed ID: 7528296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of amrinone on myocardial energetics in severe congestive heart failure.
    Baim DS
    Am J Cardiol; 1985 Jul; 56(3):16B-18B. PubMed ID: 3161318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple cyclic nucleotide phosphodiesterases in human trabecular meshwork cells.
    Zhou L; Thompson WJ; Potter DE
    Invest Ophthalmol Vis Sci; 1999 Jul; 40(8):1745-52. PubMed ID: 10393044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inotropic effects of amrinone and milrinone on contraction and relaxation of isolated cardiac muscle.
    Sys SU; Goenen MJ; Chalant CH; Brutsaert DL
    Circulation; 1986 Mar; 73(3 Pt 2):III25-35. PubMed ID: 3002662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current data regarding new positive inotropic drugs].
    Popescu P; Nanea T
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1987; 39(3):211-26. PubMed ID: 2891169
    [No Abstract]   [Full Text] [Related]  

  • 38. Specific effects of n-3 fatty acids and 8-bromo-cGMP on the cyclic nucleotide phosphodiesterase activity in neonatal rat cardiac myocytes.
    Picq M; Dubois M; Grynberg A; Lagarde M; Prigent AF
    J Mol Cell Cardiol; 1996 Oct; 28(10):2151-61. PubMed ID: 8930810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of amrinone and milrinone on calcium influx into the myocardium.
    Sutko JL; Kenyon JL; Reeves JP
    Circulation; 1986 Mar; 73(3 Pt 2):III52-8. PubMed ID: 3002664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
    Collado MC; Beleta J; Martinez E; Miralpeix M; Domènech T; Palacios JM; Hernández J
    Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.